Clinical trials in ovarian carcinoma: study methodology

被引：19
作者：
Vermorken, JB
Parmar, MKB
Brady, MF
Eisenhauer, EA
Hogberg, T
Ozols, RF
Rochon, J
Rustin, GJS
Sagae, S
Verheijen, RHM
机构：
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
10.1093/annonc/mdi963
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20 / 29
页数：10
相关论文
共 52 条
  • [1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    Alberts, DS
    Liu, PY
    Hannigan, EV
    OToole, R
    Williams, SD
    Young, JA
    Franklin, EW
    ClarkePearson, DL
    Malviya, VK
    DuBeshter, B
    Adelson, MD
    Hoskins, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
  • [2] AMSTRONG DK, 2002, P AN M AM SOC CLIN, V21, pA201
  • [3] [Anonymous], GYNECOL ONCOL
  • [4] Advanced epithelial ovarian cancer:: 1998 consensus statements
    Berek, JS
    Bertelsen, K
    du Bois, A
    Brady, MF
    Carmichael, J
    Eisenhauer, EA
    Gore, M
    Grenman, S
    Hamilton, TC
    Hansen, SW
    Harper, PG
    Horvath, G
    Kaye, SB
    Lück, HJ
    Lund, B
    McGuire, WP
    Neijt, JP
    Ozols, RF
    Parmar, MKB
    Piccart-Gebhart, MJ
    van Rijswijk, R
    Rosenberg, P
    Rustin, GJS
    Sessa, C
    Thigpen, JT
    Tropé, C
    Tuxen, MK
    Vergote, I
    Vermorken, JB
    Willemse, PHB
    [J]. ANNALS OF ONCOLOGY, 1999, 10 : 87 - 92
  • [5] Systemic treatment policies in ovarian cancer: the next 10 years
    Biagi, JJ
    Eisenhauer, EA
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 : 231 - 240
  • [6] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    Bookman, MA
    Darcy, KM
    Clarke-Pearson, D
    Boothby, RA
    Horowitz, IR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 283 - 290
  • [7] Randomised trials in ovarian cancer: trial design considerations
    Brady, MF
    Thigpen, JT
    Vermorken, JB
    Parmar, MKB
    [J]. ANNALS OF ONCOLOGY, 1999, 10 : 75 - 82
  • [8] BUYSE M, 1991, J CLIN ONCOL, V9, P1668
  • [9] Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
  • [10] The ethics of early stopping rules: Who is protecting whom?
    Cannistra, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1542 - 1545
123456